Briana Costello MD

“There is a movement underway, and it has been growing for a long time.” PROUD to be a part of the movement. #WIC #SheForShe #HeForShe 👩🏼‍⚕️🙌🏼 twitter.com/drtoniyasingh/…

In the large ROLLING STONE registry (1,005 pts, 23 Italian centers) comparing #IVL vs #atherectomy in calcified lesions, procedural success was similar, but IVL showed significantly ⬇️MACE & CV death at 30 days & 12 months. jacc.org/doi/10.1016/j.… #JACCINT @veronica_lio

@farkomd Nice- but isn’t it Kommerell?

The Kommeral diverticulum and aberrant right subclavian artery. Divided in the chest using the #Robot and brought up out the neck incision for carotid subclavian transposition

In the #Tuxedo2 #RCT of 1800 patients with #T2DM & #MVD in India undergoing #PCI, #ticagrelor not proven non-inferior to #prasugrel on PEP of #MACE Point estimates favoured prasugrel across endpoints Non-inferiority margin 5% Congrats @SripalBangalore & team #AHA25 @mmamas1973

@DrMarthaGulati Everything you just said 💯. Now we will spend another few minutes of our already minuscule amount of time with patients trying to undo these non scientific statements.

Today the Black Box was removed from ALL Menopausal Hormone Therapy (MHT). For transvaginal, I think this is reasonable, but what do we actually know about contemporary doses of transdermal & oral #MHT? I also think the statements being made are doing a huge disservice to women. This is NOT a win for women. A win would be funding a trial that studies women on contemporary doses of transdermal & oral MHT. The statement by Makary that "With the exception of vaccines or antibiotics, there's no medication that can improve the health of women on a population level more than hormone replacement therapy," is not based on fact. We just don’t know and certainly any statement on cardiac safety remains unknown for contemporary doses of transdermal and oral MHT I want to care for women using evidence based treatments. We have seen by many examples of what can happen when we don’t study women. Let’s not do this again. #womenshealth #HormoneTherapy #hearthealth #savingwomenshearts #menopause

@drjohnm This👏🏼👏🏼👏🏼👏🏼👏🏼

I don’t have a dog in this fight but geez, how did ticagrelor get such favored status? Ticagrelor loses to prasugrel in ISAR REACT It’s not like PLATO was definitive Now… TUXEDO 2 also favors prasugrel #aha25

This is what you get from Trump. Violence against people caring for your children, only because of their color and spanish accent. Witnesses say she has a work permit. Teaches kids spanish at an immersion school.

A very nice study from #EACTS2025. I will cover today on the This Week in Cardiology podcast. Once again, guidelines are too aggressive. And biased toward action.

🚨 NEW: Netflix secretly recorded an interview with Dr. Jane Goodall in March, set to air only after her death. In it, she says she wishes Trump and Elon Musk could be blasted into space… and closes with: “Don’t lose hope.” Now that’s a final message.

My #Cardiology paper of the year: Daily Step Count in @JACCJournals The optimal steps to ⬇️ CVD events is NOT THAT HIGH! Totally achievable! Its easy to get discouraged by the marathoners, bodybuilders, etc. Sure that's great, but not necessary. Do enough, the benefits follow

Agent ISR- YES!! Nearly three-quarters of the patients had intravascular image guided ISR PCI….and the outcomes were very good. Now that’s progress! Let’s next hope for rapid FDA approval of Agent coupled with wide adoption of intravascular imaging for all ISR cases.

Safety of Continuing #MRA Treatment in Patients with #HFrEF and Severe Kidney Disease In this study from the Swedish Heart Failure Registry of 33,942 HFrEF patients (EF < 40%): 📍51% received MRA, with varying rates across #eGFR levels. 📍Higher eGFR & severe HF features correlated with more MRA use. 📍MRA use didn't increase risk of renal events, all-cause ☠️, or 🏥 across eGFR levels, including severe #CKD onlinelibrary.wiley.com/doi/abs/10.100… @EJHFEiC @HFA_President @MarcoMetra @ESC_Journals

🌟Pub alert! While #preeclampsia (PE)⬆️CVD risk, how do we identify those ♀️whose arteries are already on a disease path? Led by @paquin_amelie ,we showed that PE ♀️who remain HTNsive have much worse arterial health, and may be prioritized for #CVPrev ➡️bit.ly/46pUBIK

Don’t miss this joint AHA/ACC webinar! Achieving gender equity in cardiology requires collaboration with our male allies! Join us to discuss what #HeForShe means in cardiology ! #AHAWIC #ACCWIC @gina_lundberg @PamTaubMD @RBP0612

📷 "Honored to be in the company of these exceptional #WomenInCardiology. A memorable evening exchanging stories and charting the course for the WIC community's journey ahead. 💙👩‍⚕️ #CardioQueens #HeartbeatsAndHighHeels" 👠🩺#BarbiesinCardiology😍🥰💃#TCACC

Big news #ESC2023 and @NEJM In a placebo-controlled randomized trial of people with obesity + heart failure (with preserved ejection fraction). semaglutide (Wegovy) markedly improved symptoms, exercise time, reduced inflammatory markers (and weight loss) nejm.org/doi/full/10.10…

#ESCCongress #JACC LBCT SimPub: New from #DAPA-HF & #DELIVER: Benefit-to-risk ratio may favor continuation of #SGLT2i dapagliflozin in #HeartFailure pts w/ deterioration in kidney function to eGFR<25ml/min/1.73m2 bit.ly/3QU3AwK @safchat @mvaduganathan @scottsolomon

Late breaking at #ESCCongress: In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo. Full STEP-HFpEF trial:

An historic Class 1A recommendation for HFpEF. Expected but still remarkable. #ESCCongress @escardio Proud of the many who brought this forward for our patients. @MkosiborodMD @MidAmericaHeart @saintlukeskc

Multicenter real-world audit of #FFRCT by #YesCCT in UK's NICE guidelines shows that PPV of FFRCT was 49%, & its use was costlier vs stress tests. A cautious approach is implied for FFRCT roll-out in clinical practice. bit.ly/3P2NMq6 #JACCIMG #CardioTwitter

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: @JACCJournals Guidelines are detailed: reading it slowly Please, read full doc! Thread #14: Medical management: What is going on w antiplatelet therapy? 🥸📷👇